Arcus Biosciences (NYSE:RCUS) Issues Earnings Results

Arcus Biosciences (NYSE:RCUS) released its quarterly earnings results on Tuesday. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.24), Bloomberg Earnings reports. Arcus Biosciences had a negative return on equity of 22.72% and a negative net margin of 613.46%. The firm had revenue of $1.75 million for the quarter, compared to analyst estimates of $4.54 million.

Shares of Arcus Biosciences stock traded down $0.03 during trading hours on Wednesday, reaching $6.72. 448,130 shares of the company were exchanged, compared to its average volume of 140,835. Arcus Biosciences has a 1 year low of $6.30 and a 1 year high of $16.06. The firm has a fifty day moving average of $8.30. The company has a market capitalization of $304.62 million, a price-to-earnings ratio of -4.70 and a beta of 1.02.

In other Arcus Biosciences news, CEO Terry J. Rosen bought 41,540 shares of the company’s stock in a transaction that occurred on Tuesday, June 4th. The shares were purchased at an average price of $7.91 per share, with a total value of $328,581.40. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Kathryn E. Falberg bought 32,065 shares of the company’s stock in a transaction that occurred on Monday, June 10th. The stock was acquired at an average cost of $8.07 per share, for a total transaction of $258,764.55. The disclosure for this purchase can be found here. Insiders have bought 140,343 shares of company stock worth $1,120,078 in the last ninety days. Corporate insiders own 19.23% of the company’s stock.

A number of research analysts have commented on RCUS shares. ValuEngine upgraded Arcus Biosciences from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Zacks Investment Research raised Arcus Biosciences from a “hold” rating to a “buy” rating and set a $9.25 price objective on the stock in a research report on Thursday, July 4th. Citigroup cut their price objective on Arcus Biosciences from $25.00 to $15.00 and set an “in-line” rating on the stock in a research report on Wednesday, June 5th. Finally, Svb Leerink reaffirmed an “outperform” rating on shares of Arcus Biosciences in a research report on Friday, May 3rd. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $16.56.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial.

See Also: Strike Price

Earnings History for Arcus Biosciences (NYSE:RCUS)

Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with's FREE daily email newsletter.